Loading organizations...
SynOx Therapeutics Ltd is focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
SynOx Therapeutics has raised $246.0M across 4 funding rounds.
SynOx Therapeutics has raised $246.0M in total across 4 funding rounds.
SynOx Therapeutics has raised $246.0M in total across 4 funding rounds.
SynOx Therapeutics's investors include Oscar Slotboom, Rob de Ree, Forbion, Red Tree Venture Capital, Hercules Capital, HealthCap, Medicxi.
SynOx Therapeutics has raised $246.0M across 4 funding rounds. Most recently, it raised $92.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2024 | $92M Series B | — | Oscar Slotboom, ROB DE REE, Forbion, RED Tree Venture Capital | Announced |
| Apr 30, 2024 | $35M Debt Financing | Hercules Capital | — | Announced |
| Apr 1, 2024 | $75M Series B | — | Oscar Slotboom, ROB DE REE, Forbion, RED Tree Venture Capital | Announced |
| Nov 1, 2020 | $44M Series A | HealthCap, Medicxi | Oscar Slotboom, ROB DE REE, Forbion | Announced |
SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody targeting CSF-1R, primarily for treating tenosynovial giant cell tumor (TGCT) and other macrophage-driven diseases.[1][2][3] Headquartered in Dublin and Oxford, it serves patients with rare, debilitating conditions like TGCT—a painful, disability-causing tumor—by addressing unmet needs through a well-tolerated therapy with promising efficacy demonstrated in prior trials.[1][2][3] The company is backed by premier life sciences investors including Forbion, HealthCap, Bioqube Ventures, Gilde Healthcare, and Medicxi, with over $170 million in total funding, including a recent $92 million round and up to $35 million debt financing from Hercules Capital to support registration and commercialization.[2][4]
SynOx's growth momentum stems from licensing emactuzumab exclusively from Roche in 2020, positioning it at a "critical and exciting stage" with an experienced team driving late-stage development toward global approval.[1][3][4]
SynOx Therapeutics was founded in November 2020 after securing exclusive worldwide rights to emactuzumab from Roche, building on the antibody's established safety profile and efficacy data in TGCT patients.[1][3] The idea emerged from Roche's prior development, where emactuzumab showed remarkable results in this rare disease, prompting SynOx to focus solely on advancing it as a best-in-class option.[1][2]
Led by CEO Ray Barlow and an executive team with deep expertise in biologics development, approval, and commercialization, the company is chaired by Philip Astley-Sparke, a serial biotech entrepreneur who co-founded Replimune and led BioVex to approval of the first U.S./EU oncolytic therapy.[1] Early traction includes strong investor backing and debt financing, marking pivotal steps toward Phase 3 trials and market entry.[4]
SynOx rides the wave of precision oncology and macrophage-targeted therapies, capitalizing on growing recognition of CSF-1R inhibition for rare tumors like TGCT, where limited treatments exist.[1][2] Timing is ideal amid rising focus on orphan drugs—TGCT affects few but offers fast-track approvals, high pricing potential, and expansion to broader macrophage-mediated diseases like certain cancers or inflammatory conditions.[3][5]
Market forces favor SynOx: biopharma's shift toward asset-centric spinouts from big pharma (e.g., Roche licensing), coupled with investor appetite for late-stage biotech with de-risked profiles.[1][4] It influences the ecosystem by validating CSF-1R as a target, potentially accelerating similar therapies and filling gaps in rare disease care.[2]
SynOx is primed for regulatory milestones, with upcoming clinical data, FDA/EMA filings, and commercialization push funded by recent debt—positioning emactuzumab as the TGCT drug of choice.[1][4] Trends like AI-driven trial design, orphan drug incentives, and macrophage therapy expansion will shape its path, possibly broadening to new indications amid a biotech funding rebound.
Its influence could grow by pioneering CSF-1R dominance, delivering life-improving options for underserved patients and rewarding investors with a high-value exit, echoing the journeys of its leaders' prior successes.[1][3]
